1.42 0.03 (2.16%) | 02-06 10:04 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.04 ![]() |
1-year : | 2.37 ![]() |
Resists | First : | 1.75 ![]() |
Second : | 2.02 ![]() |
Pivot price | 1.46 ![]() |
|||
Supports | First : | 1.29 | Second : | 1.08 |
MAs | MA(5) : | 1.38 ![]() |
MA(20) : | 1.48 ![]() |
MA(100) : | 2.26 ![]() |
MA(250) : | 2.26 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 23.3 ![]() |
D(3) : | 18.6 ![]() |
RSI | RSI(14): 40.8 ![]() |
|||
52-week | High : | 17.75 | Low : | 1.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ATNF ] has closed above bottom band by 34.8%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.41 - 1.42 | 1.42 - 1.42 |
Low: | 1.36 - 1.36 | 1.36 - 1.37 |
Close: | 1.38 - 1.39 | 1.39 - 1.4 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Mon, 30 Dec 2024
Stock offering fuels company's leap to iGaming - The Business Journals
Fri, 27 Dec 2024
180 Life Sciences announces $2.9 million securities offering - Investing.com
Fri, 25 Oct 2024
Elray Resources Announces Strategic Sale of Crypto iGaming Technology - StockTitan
Fri, 25 Oct 2024
Elray Resources Announces Strategic Sale of Crypto iGaming Technology - Yahoo Finance
Wed, 16 Oct 2024
Nasdaq Moves Higher; Morgan Stanley Profit Beats Estimates - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 1 (M) |
Held by Insiders | 4.3 (%) |
Held by Institutions | 3.4 (%) |
Shares Short | 139 (K) |
Shares Short P.Month | 73 (K) |
EPS | 7.98 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.24 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -63.5 % |
Return on Equity (ttm) | -398.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.78 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -4 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | 0.17 |
PEG Ratio | 0 |
Price to Book value | -5.92 |
Price to Sales | 0 |
Price to Cash Flow | -1.07 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |